This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nutropin/Increlex - AGHD

Ipsen SA

Drug Names(s): growth hormone/IGF, rhGH/rhIGF-1, somatropin/mecasermin

Description: Growth Hormone and IGF-1 combination product contains Genentech's recombinant human growth hormone Nutropin AQ (somatropin (rDNA origin)) and Tercica's recombinant insulin-like growth factor-1 Increlex (mecasermin (rDNA origin) injection).

Per a company representative, the ratio of GH/IGF-1 has not yet been determined for this indication.

Deal Structure: On July 10, 2007, Tercica announced an agreement with Genentech for the development, manufacture and worldwide commercialization of two products containing Genentech's Nutropin AQ and Tercica's Increlex for the treatment of short stature, adult growth hormone deficiency (AGHD), and potentially other metabolic disorders. Genentech has opt-in rights after Phase II development.

In June 2008, Tercica announced that Tercica and Ipsen entered into a definitive merger agreement by which an affiliate of Ipsen would acquire all of the shares of Tercica common stock that Ipsen does not currently own at a price of $9.00 per share in cash, which values Tercica at approximately $663 million.

In October 2008, Ipsen completed the acquisition of Tercica.

In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8...See full deal structure in Biomedtracker

Partners: Roche Holding AG

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug